Kamada Ltd ( (KMDA) ) has released its Q2 earnings. Here is a breakdown of the information Kamada Ltd presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kamada Ltd. is a global biopharmaceutical company specializing in plasma-derived therapies for rare and serious conditions, with a strong presence in the specialty plasma-derived field. In its latest earnings report, Kamada announced robust financial results for the second quarter and first half of 2025, highlighting an 11% year-over-year increase in total revenues and a 35% rise in adjusted EBITDA. The company reported first-half revenues of $88.8 million and adjusted EBITDA of $22.5 million, reflecting a 25% margin of revenues. Kamada also announced FDA approval for its plasma collection center in Houston, Texas, which is set to begin commercial sales, and emphasized its focus on securing commercial-stage business development opportunities. Looking ahead, Kamada has raised its full-year profitability guidance, expecting adjusted EBITDA between $40 million and $44 million, while maintaining its revenue guidance of $178 million to $182 million for 2025. The company continues to invest in strategic growth pillars, including organic growth, business development, and plasma collection operations, to support long-term profitable growth.